Christian Pilarsky vividly remembers the moment, in 2022, when he realized that his technique for modelling pancreatic cancer had finally worked. A molecular biologist at the University Hospital ...
Silexion Therapeutics completes initial study of SIL-204 in pancreatic cancer models, assessing tumor growth and metastasis. Results expected in March 2025. Silexion Therapeutics Corp. announced the ...
A phase I dose escalation study of carbon-ion radiotherapy for pancreatic cancer. This is an ASCO Meeting Abstract from the 2023 ASCO Gastrointestinal Cancers Symposium. This abstract does not include ...
An international team of researchers led by Max Delbrück Center Scientific Director Professor Maike Sander, MD, has for the first time developed an organoid model of human pluripotent stem ...
Silexion Therapeutics Corp. announced promising results from preclinical studies of its RNA interference therapy, SIL204, for KRAS-driven pancreatic cancer. The research, conducted in orthotopic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results